Chapter title |
Irritable Bowel Syndrome: Pathophysiology and Current Therapeutic Approaches
|
---|---|
Chapter number | 102 |
Book title |
Gastrointestinal Pharmacology
|
Published in |
Handbook of experimental pharmacology, January 2016
|
DOI | 10.1007/164_2016_102 |
Pubmed ID | |
Book ISBNs |
978-3-31-956359-6, 978-3-31-956360-2
|
Authors |
Michael Camilleri, Alexander C. Ford, Camilleri, Michael, Ford, Alexander C. |
Abstract |
Irritable bowel syndrome (IBS) is a prevalent condition affecting 10-20% of adults in most countries; IBS results in significant morbidity and health care costs. IBS is a disorder of the brain-gut axis, and recent insights into the pathophysiological mechanisms include altered bile acid metabolism, neurohormonal regulation, immune dysfunction, alterations in the epithelial barrier, and secretory properties of the gut. There remains a significant unmet need for effective treatments, particularly for the pain component of IBS, although the introduction of drugs directed at secretion, motility, and a nonabsorbable antibiotic provides an option for the bowel dysfunction in IBS. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 84 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 17 | 20% |
Student > Master | 8 | 10% |
Student > Doctoral Student | 8 | 10% |
Other | 7 | 8% |
Researcher | 5 | 6% |
Other | 13 | 15% |
Unknown | 26 | 31% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 16 | 19% |
Nursing and Health Professions | 13 | 15% |
Pharmacology, Toxicology and Pharmaceutical Science | 6 | 7% |
Agricultural and Biological Sciences | 4 | 5% |
Biochemistry, Genetics and Molecular Biology | 4 | 5% |
Other | 9 | 11% |
Unknown | 32 | 38% |